[YINSON] QoQ Cumulative Quarter Result on 30-Apr-2024 [#1]

Stock
[YINSON] YINSON HOLDINGS BHD
Announcement Date
19-Jun-2024
Admission Sponsor
-
Sponsor
-
Financial Year
31-Jan-2025
Quarter
30-Apr-2024 [#1]
Profit Trend
QoQ- -78.94%
YoY- -2.4%
Quarter Report
Latest QR
Upcoming QR
YINSON's Result
YINSON's Financial Summary
View:
Show?
Cumulative Result
31/07/24 30/04/24 31/01/24 31/10/23 31/07/23 30/04/23 31/01/23 CAGR
Revenue 4,356,000 2,214,000 11,646,000 8,944,000 6,131,000 3,018,000 6,324,000 -22.02%
PBT 690,000 357,000 1,695,000 1,098,000 745,000 296,000 845,000 -12.64%
Tax -178,000 -108,000 -553,000 -351,000 -276,000 -102,000 -257,000 -21.73%
NP 512,000 249,000 1,142,000 747,000 469,000 194,000 588,000 -8.82%
-
NP to SH 406,000 203,000 964,000 686,000 438,000 208,000 586,000 -21.71%
-
Tax Rate 25.80% 30.25% 32.63% 31.97% 37.05% 34.46% 30.41% -
Total Cost 3,844,000 1,965,000 10,504,000 8,197,000 5,662,000 2,824,000 5,736,000 -23.43%
-
Net Worth 5,686,063 6,111,451 5,435,824 5,551,856 4,999,396 3,307,865 4,141,914 23.54%
Dividend
31/07/24 30/04/24 31/01/24 31/10/23 31/07/23 30/04/23 31/01/23 CAGR
Div 60,169 29,523 87,205 58,134 58,132 - 57,928 2.56%
Div Payout % 14.82% 14.54% 9.05% 8.47% 13.27% - 9.89% -
Equity
31/07/24 30/04/24 31/01/24 31/10/23 31/07/23 30/04/23 31/01/23 CAGR
Net Worth 5,686,063 6,111,451 5,435,824 5,551,856 4,999,396 3,307,865 4,141,914 23.54%
NOSH 3,185,684 3,184,401 3,064,331 3,064,098 3,064,018 3,063,864 3,053,682 2.86%
Ratio Analysis
31/07/24 30/04/24 31/01/24 31/10/23 31/07/23 30/04/23 31/01/23 CAGR
NP Margin 11.75% 11.25% 9.81% 8.35% 7.65% 6.43% 9.30% -
ROE 7.14% 3.32% 17.73% 12.36% 8.76% 6.29% 14.15% -
Per Share
31/07/24 30/04/24 31/01/24 31/10/23 31/07/23 30/04/23 31/01/23 CAGR
RPS 144.79 74.99 400.64 307.70 210.93 144.15 218.34 -23.97%
EPS 11.20 5.60 28.50 20.10 12.80 6.10 16.60 -23.09%
DPS 2.00 1.00 3.00 2.00 2.00 0.00 2.00 0.00%
NAPS 1.89 2.07 1.87 1.91 1.72 1.58 1.43 20.45%
Adjusted Per Share Value based on latest NOSH - 3,184,401
31/07/24 30/04/24 31/01/24 31/10/23 31/07/23 30/04/23 31/01/23 CAGR
RPS 135.91 69.08 363.37 279.06 191.29 94.16 197.31 -22.02%
EPS 12.67 6.33 30.08 21.40 13.67 6.49 18.28 -21.69%
DPS 1.88 0.92 2.72 1.81 1.81 0.00 1.81 2.56%
NAPS 1.7741 1.9068 1.696 1.7322 1.5599 1.0321 1.2923 23.54%
Price Multiplier on Financial Quarter End Date
31/07/24 30/04/24 31/01/24 31/10/23 31/07/23 30/04/23 31/01/23 CAGR
Date 31/07/24 30/04/24 31/01/24 31/10/23 31/07/23 28/04/23 31/01/23 -
Price 2.39 2.45 2.57 2.45 2.55 2.62 2.69 -
P/RPS 1.65 3.27 0.64 0.80 1.21 1.82 1.23 21.65%
P/EPS 17.71 35.63 7.75 10.38 16.92 26.37 13.30 21.05%
EY 5.65 2.81 12.90 9.63 5.91 3.79 7.52 -17.36%
DY 0.84 0.41 1.17 0.82 0.78 0.00 0.74 8.82%
P/NAPS 1.26 1.18 1.37 1.28 1.48 1.66 1.88 -23.43%
Price Multiplier on Announcement Date
31/07/24 30/04/24 31/01/24 31/10/23 31/07/23 30/04/23 31/01/23 CAGR
Date 30/09/24 19/06/24 22/03/24 14/12/23 29/09/23 23/06/23 23/03/23 -
Price 2.68 2.34 2.45 2.50 2.48 2.56 2.42 -
P/RPS 1.85 3.12 0.61 0.81 1.18 1.78 1.11 40.61%
P/EPS 19.86 34.03 7.39 10.59 16.46 25.77 11.96 40.27%
EY 5.04 2.94 13.54 9.44 6.08 3.88 8.36 -28.65%
DY 0.75 0.43 1.22 0.80 0.81 0.00 0.83 -6.53%
P/NAPS 1.42 1.13 1.31 1.31 1.44 1.62 1.69 -10.96%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment